Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
Systematic review of 21 studies: slowing fetal growth velocity predicted small for gestational age poorly (AC sensitivity 0.22, specificity 0.92) but was moderately associated with adverse outcomes, eg perinatal death (pooled OR 3.92). No gain over biometry.
Meta-analysisn = 185,441 pregnancies
D'Alberti et al. Fetal growth velocity as a predictor of small for gestational age at birth and adverse perinatal outcomes: systematic review and meta-analysisSystematic review of 28 studies (4423 participants) of urinary cell-free DNA for non-urothelial cancers: pooled sensitivity 0.80 and specificity 0.96, with high heterogeneity; limited post-treatment ucfDNA fall predicted poor prognosis (pooled HR 2.76).
Meta-analysisn = 4,423
Yajima et al. Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysisMeta-analysis of five RCTs (2380 women, FIGO stage III-IV ovarian cancer): neoadjuvant chemotherapy with interval surgery vs primary debulking showed no difference in OS (HR 1.00) or PFS (HR 1.03), with fewer grade ≥3 perioperative complications (RR 0.43).
Meta-analysisn = 2,380
Secchi et al. Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysisSystematic review and pooled analysis of 26 studies (1647 patients) of repeat colonoscopy after a failed attempt not due to poor bowel preparation: pooled caecal intubation rate on reattempt was 95.7% (95% CI 94.2-97.2%), with no significant covariates on meta-regression.
Meta-analysisn = 1,647
Saeed et al. Utility of repeat colonoscopy attempt after failed colonoscopy: a systematic review and pooled analysisIn 1180 high-risk adults undergoing major surgery, a biomarker-guided KDIGO preventive care strategy vs usual care reduced moderate or severe AKI within 72 h (14.4% vs 22.3%; OR 0.57, 95% CI 0.40-0.79; 1176 analysed), with no difference in adverse events.
RCTn = 1,180
Zarbock et al. A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trialLong-term analysis of GRIPHON and its open-label extension in 953 selexipag-treated patients with pulmonary arterial hypertension: in 574 long-term patients (median follow-up 54 months), estimated 5-year survival was 74%; 39% stopped selexipag due to adverse events.
RCTn = 953
McLaughlin et al. Evaluating oral selexipag in pulmonary arterial hypertension: Insights on survival, safety, and dosing patterns from the complete observation period of GRIPHON and its open-label extensionMeta-analysis of 6 RCTs (522 obese adults with asthma): weight loss over 12-24 weeks improved ACQ score (-0.75), quality of life and FEV1 (+4.65%), but benefits were not sustained at 52 weeks; greater effect with ≥10% weight loss (subgroup).
Meta-analysisn = 522
Rybka-Fraczek et al. Effect of Weight Loss on Asthma in Obese Adult Patients With Asthma: A Systematic Review and Meta-AnalysisPhase 1 RCT of a Hendra virus sG vaccine (HeV-sG-V) against Nipah virus in 192 healthy adults vs placebo: no serious adverse events; mainly mild-to-moderate injection site pain. Two doses were immunogenic (highest with 100 μg 28 days apart); one dose was not sufficient.
RCTn = 192
Frenck et al. Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 studyPilot RCT of a smartphone alcohol approach bias modification app vs sham training in 188 adults ≥55 drinking at hazardous levels: no significant difference in past-week drinks at week 4 (β -1.90, p=.43); 56% retention. Feasibility and acceptability were good.
RCTn = 188
Bolt et al. AAT-App+: A double-blind, pilot randomised controlled trial of a novel personalised smartphone intervention to reduce hazardous and harmful alcohol consumption among middle-older adultsOpen-label RCT of 176 adults with varicose veins and venous reflux: oral Vitis vinifera seed extract plus lifestyle changes vs lifestyle changes alone for 12 weeks gave significantly greater reductions in mean venous reflux time, VCSS and CIVIQ-14 scores.
RCTn = 176
Bae et al. Vitis vinifera seed extract reduces venous reflux time in patients with varicose veins: VICTORY randomized controlled trial